 Vaughn Browne
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Altitude | 12 | 2020 | 485 | 1.250 |
Why?
| | Uterine Artery | 6 | 2020 | 79 | 0.950 |
Why?
| | Cardiac Tamponade | 1 | 2022 | 12 | 0.800 |
Why?
| | Regional Blood Flow | 3 | 2015 | 473 | 0.490 |
Why?
| | Fetal Growth Retardation | 5 | 2013 | 564 | 0.480 |
Why?
| | Fetal Hypoxia | 2 | 2015 | 54 | 0.460 |
Why?
| | Pre-Eclampsia | 2 | 2020 | 189 | 0.430 |
Why?
| | Fetal Development | 2 | 2015 | 296 | 0.390 |
Why?
| | Papillary Muscles | 4 | 2004 | 13 | 0.370 |
Why?
| | Fetus | 2 | 2015 | 806 | 0.360 |
Why?
| | Vascular Resistance | 2 | 2020 | 372 | 0.350 |
Why?
| | Biological Evolution | 1 | 2015 | 467 | 0.350 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2011 | 68 | 0.330 |
Why?
| | Hypoxia | 6 | 2017 | 1112 | 0.300 |
Why?
| | Myocardial Contraction | 3 | 1997 | 339 | 0.270 |
Why?
| | Pregnancy Complications | 3 | 2017 | 525 | 0.260 |
Why?
| | Ultrasonography | 4 | 2017 | 750 | 0.240 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 163 | 0.230 |
Why?
| | Pregnancy | 13 | 2020 | 6727 | 0.230 |
Why?
| | Bolivia | 6 | 2017 | 65 | 0.210 |
Why?
| | Fetal Heart | 3 | 2004 | 55 | 0.210 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2020 | 14 | 0.160 |
Why?
| | Acclimatization | 2 | 2013 | 177 | 0.160 |
Why?
| | Birth Weight | 2 | 2014 | 514 | 0.150 |
Why?
| | Uterus | 1 | 2020 | 215 | 0.150 |
Why?
| | Altitude Sickness | 2 | 2013 | 153 | 0.140 |
Why?
| | Paracentesis | 1 | 2017 | 14 | 0.140 |
Why?
| | Gestational Age | 5 | 2014 | 902 | 0.130 |
Why?
| | Receptors, Adrenergic, beta | 1 | 1997 | 127 | 0.130 |
Why?
| | Education, Premedical | 1 | 2016 | 5 | 0.130 |
Why?
| | Receptors, Erythropoietin | 1 | 2017 | 20 | 0.130 |
Why?
| | Heart | 2 | 1997 | 653 | 0.130 |
Why?
| | Ultrasonics | 1 | 2016 | 49 | 0.130 |
Why?
| | Computer-Assisted Instruction | 1 | 2017 | 65 | 0.130 |
Why?
| | Abscess | 1 | 2017 | 74 | 0.130 |
Why?
| | Phantoms, Imaging | 1 | 2017 | 151 | 0.120 |
Why?
| | Ultrasonography, Doppler | 2 | 2020 | 123 | 0.120 |
Why?
| | Erythropoietin | 1 | 2017 | 95 | 0.120 |
Why?
| | Pulse | 1 | 2015 | 23 | 0.120 |
Why?
| | Palpation | 1 | 2015 | 15 | 0.120 |
Why?
| | Calcium | 2 | 2004 | 1197 | 0.120 |
Why?
| | Simulation Training | 1 | 2017 | 98 | 0.120 |
Why?
| | Adaptation, Physiological | 2 | 2017 | 549 | 0.120 |
Why?
| | Receptor, Endothelin A | 1 | 2014 | 65 | 0.110 |
Why?
| | Femoral Artery | 1 | 2015 | 179 | 0.110 |
Why?
| | Vascular Diseases | 1 | 2017 | 243 | 0.110 |
Why?
| | Teaching | 1 | 2015 | 223 | 0.100 |
Why?
| | Placenta | 1 | 2020 | 749 | 0.100 |
Why?
| | Education, Medical, Undergraduate | 1 | 2015 | 182 | 0.100 |
Why?
| | Optic Nerve | 1 | 2013 | 64 | 0.100 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 197 | 0.100 |
Why?
| | PPAR gamma | 1 | 2013 | 182 | 0.100 |
Why?
| | Blood Flow Velocity | 2 | 2011 | 412 | 0.100 |
Why?
| | Students, Medical | 1 | 2017 | 335 | 0.100 |
Why?
| | Enzymes | 1 | 2011 | 67 | 0.090 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2013 | 157 | 0.090 |
Why?
| | Infant, Small for Gestational Age | 1 | 2011 | 91 | 0.090 |
Why?
| | Students | 1 | 2016 | 624 | 0.090 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2011 | 32 | 0.090 |
Why?
| | Heart Rate | 1 | 2015 | 820 | 0.090 |
Why?
| | Live Birth | 1 | 2011 | 65 | 0.090 |
Why?
| | Iliac Artery | 1 | 2011 | 55 | 0.090 |
Why?
| | Angiostatic Proteins | 1 | 2010 | 5 | 0.090 |
Why?
| | Angiogenic Proteins | 1 | 2010 | 16 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2017 | 3540 | 0.080 |
Why?
| | Homeostasis | 1 | 2014 | 619 | 0.080 |
Why?
| | Stillbirth | 1 | 2011 | 72 | 0.080 |
Why?
| | Female | 16 | 2020 | 72785 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 973 | 0.080 |
Why?
| | Young Adult | 7 | 2020 | 13126 | 0.080 |
Why?
| | Humans | 16 | 2022 | 136750 | 0.080 |
Why?
| | Ultrasonography, Prenatal | 1 | 2011 | 284 | 0.080 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2014 | 2184 | 0.070 |
Why?
| | Sheep | 4 | 2004 | 855 | 0.070 |
Why?
| | Interleukin-1beta | 1 | 2010 | 371 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2011 | 1316 | 0.070 |
Why?
| | Adult | 11 | 2020 | 37626 | 0.070 |
Why?
| | Antioxidants | 1 | 2011 | 584 | 0.070 |
Why?
| | Models, Biological | 1 | 2015 | 1773 | 0.070 |
Why?
| | Premature Birth | 1 | 2011 | 331 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 5419 | 0.070 |
Why?
| | Ginkgo biloba | 1 | 2005 | 8 | 0.060 |
Why?
| | Carbonic Anhydrase Inhibitors | 1 | 2005 | 14 | 0.060 |
Why?
| | Acetazolamide | 1 | 2005 | 26 | 0.060 |
Why?
| | Plant Preparations | 1 | 2005 | 36 | 0.060 |
Why?
| | Phytotherapy | 1 | 2005 | 83 | 0.060 |
Why?
| | Middle Aged | 3 | 2022 | 33225 | 0.050 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2605 | 0.050 |
Why?
| | Troponin I | 1 | 2004 | 81 | 0.050 |
Why?
| | Cytokines | 1 | 2010 | 2084 | 0.050 |
Why?
| | Indians, South American | 2 | 2013 | 25 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2017 | 1936 | 0.040 |
Why?
| | Electric Stimulation | 2 | 2004 | 264 | 0.040 |
Why?
| | Cohort Studies | 3 | 2020 | 5703 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2017 | 3264 | 0.040 |
Why?
| | Colforsin | 1 | 1997 | 53 | 0.040 |
Why?
| | Isoproterenol | 1 | 1997 | 113 | 0.030 |
Why?
| | Isradipine | 1 | 1997 | 4 | 0.030 |
Why?
| | Ryanodine | 1 | 1997 | 15 | 0.030 |
Why?
| | Heart Ventricles | 2 | 2004 | 785 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1997 | 133 | 0.030 |
Why?
| | Cyclic AMP | 1 | 1997 | 234 | 0.030 |
Why?
| | Organ Size | 1 | 1997 | 477 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2017 | 131 | 0.030 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 1 | 1997 | 73 | 0.030 |
Why?
| | Calcium Channels | 1 | 1997 | 159 | 0.030 |
Why?
| | Reference Values | 1 | 1997 | 816 | 0.030 |
Why?
| | Calcium Channels, L-Type | 1 | 1997 | 118 | 0.030 |
Why?
| | Muscle Proteins | 1 | 1997 | 228 | 0.030 |
Why?
| | California | 1 | 2017 | 429 | 0.030 |
Why?
| | Equipment Design | 1 | 2017 | 521 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1997 | 1089 | 0.030 |
Why?
| | Ventricular Function, Right | 1 | 1997 | 282 | 0.030 |
Why?
| | Receptor, Endothelin B | 1 | 2014 | 51 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 851 | 0.030 |
Why?
| | Receptors, Endothelin | 1 | 2014 | 51 | 0.030 |
Why?
| | Radiology | 1 | 2017 | 180 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 1997 | 695 | 0.030 |
Why?
| | Universities | 1 | 2016 | 432 | 0.030 |
Why?
| | Mentoring | 1 | 2016 | 144 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 1997 | 533 | 0.030 |
Why?
| | Tibet | 1 | 2013 | 27 | 0.030 |
Why?
| | Gene Frequency | 1 | 2014 | 520 | 0.030 |
Why?
| | South America | 1 | 2013 | 59 | 0.030 |
Why?
| | Intracranial Pressure | 1 | 2013 | 47 | 0.020 |
Why?
| | Intracranial Hypertension | 1 | 2013 | 38 | 0.020 |
Why?
| | Genetic Association Studies | 1 | 2014 | 375 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2014 | 304 | 0.020 |
Why?
| | Linear Models | 1 | 2014 | 845 | 0.020 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 412 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2013 | 6031 | 0.020 |
Why?
| | Geography | 1 | 2011 | 198 | 0.020 |
Why?
| | Selection, Genetic | 1 | 2013 | 264 | 0.020 |
Why?
| | Placenta Growth Factor | 1 | 2010 | 24 | 0.020 |
Why?
| | Hemoglobins | 1 | 2013 | 353 | 0.020 |
Why?
| | Pregnancy Proteins | 1 | 2010 | 36 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 71 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 1007 | 0.020 |
Why?
| | Incidence | 1 | 2017 | 2797 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 216 | 0.020 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2010 | 253 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2829 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 530 | 0.020 |
Why?
| | Pedigree | 1 | 2010 | 514 | 0.020 |
Why?
| | Genotype | 1 | 2014 | 1914 | 0.020 |
Why?
| | Animals | 4 | 2004 | 36836 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 844 | 0.020 |
Why?
| | Interleukin-10 | 1 | 2010 | 302 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 4012 | 0.020 |
Why?
| | Clinical Competence | 1 | 2015 | 1090 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1455 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1786 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5105 | 0.020 |
Why?
| | Male | 4 | 2017 | 67305 | 0.020 |
Why?
| | Health Status | 1 | 2011 | 788 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 778 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4145 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2010 | 1242 | 0.010 |
Why?
| | Colorado | 1 | 2015 | 4512 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2004 | 40 | 0.010 |
Why?
| | Statistics, Nonparametric | 1 | 2005 | 431 | 0.010 |
Why?
| | Cardiac Output | 1 | 2004 | 164 | 0.010 |
Why?
| | Actin Cytoskeleton | 1 | 2004 | 101 | 0.010 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 135 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2412 | 0.010 |
Why?
| | Risk Assessment | 1 | 2010 | 3432 | 0.010 |
Why?
| | Infant | 1 | 2014 | 9395 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2005 | 1982 | 0.010 |
Why?
| | Phosphorylation | 1 | 2004 | 1758 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2013 | 10747 | 0.010 |
Why?
| | Prospective Studies | 1 | 2010 | 7572 | 0.010 |
Why?
| | Risk Factors | 1 | 2010 | 10330 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 21380 | 0.010 |
Why?
| | Aged | 1 | 2013 | 23800 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1997 | 2051 | 0.010 |
Why?
| | Oxygen | 1 | 1997 | 930 | 0.010 |
Why?
|
|
Browne's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|